Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer
Closed for comments This consultation ended on at Request commenting lead permission
5 Implementation
NICE intends to develop tools, in association with relevant stakeholders, to help organisations put this guidance into practice.
In addition, NICE will support this guidance through a range of activities to promote the recommendations for further research. The research proposed will be considered for developing specific research study protocols as appropriate. NICE will also incorporate the research recommendations in section 4 into its guidance research recommendations database and highlight these recommendations to public research bodies.
Exact Sciences and Myriad Genetics have offered their tumour profiling tests to the NHS under access proposals that make each test available to the NHS at a revised price. The proposal prices are commercial in confidence. It is the responsibility of the companies to communicate details of their proposal to the relevant NHS organisations.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions